Liquidia (LQDA) Property, Plant & Equipment (Net) Growth (1y) (2020 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Property, Plant & Equipment (Net) Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 7.44% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | 9.71% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 1.99% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | 2.94% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 1.35% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 13.89% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | -11.15% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 41.67% |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 262.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 262.21% |
| Mar 31, 2026 | 145.62% |
| Dec 31, 2025 | 42.73% |
| Sep 30, 2025 | 37.51% |
| Jun 30, 2025 | 49.37% |
| Mar 31, 2025 | 52.15% |
| Dec 31, 2024 | 85.22% |
| Sep 30, 2024 | 76.91% |
| Jun 30, 2024 | 53.13% |
| Mar 31, 2024 | 28.30% |
| Dec 31, 2023 | 7.93% |
| Sep 30, 2023 | 11.59% |
| Jun 30, 2023 | -1.14% |
| Mar 31, 2023 | -5.81% |
| Dec 31, 2022 | -17.26% |
| Sep 30, 2022 | -27.68% |
| Jun 30, 2022 | -28.25% |
| Mar 31, 2022 | -26.72% |
| Dec 31, 2021 | -26.28% |
| Dec 31, 2020 | -26.46% |